Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Comprehensive Cancer Center of Wake Forest University
ClinicalTrials.gov Identifier:
NCT00072579
First received: November 4, 2003
Last updated: June 4, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2007
  Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)